Whole exome sequencing (WES) provides coverage of more than 95% of the exons, (the expressed or the protein-coding regions of the genome), which harbor the majority of the large genetic variants and single nucleotide polymorphisms (SNPs) associated with human disease phenotypes.1 Of the ~3 billion bases that comprise the human genome, only about 1% is represented by coding sequences.1 By focusing on this most relevant portion of the genome, WES offers researchers the ability to use sequencing and analysis resources more efficiently. WES strategy starts by narrowing down the details of variants to be studied by filtering against databases such as HapMap, from the approximately 3.5 million SNPs identified in the human genome project. This focus enables a simpler way for discovery and validation of causative genes and common and rare variants. Exome sequencing has been proven useful in the identification of mutations involved in rare Mendelian diseases.2